Shionogi lifts first-half net profit by about 44% and raises full-year outlook
Japan's Shionogi reported higher revenue and net profit for the half year to September 30 and issued forecasts for the year to March 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Japanese drugmaker Shionogi & Co. reported first-half results for the period ended September 30, 2026, according to Dow Jones Newswires. Revenue rose to 350.38 billion yen from 212.97 billion a year earlier. Operating profit reached 115.24 billion yen against 73.98 billion, while net profit climbed to 119.55 billion yen from 83.00 billion. Earnings per share were 140.47 yen, compared with 97.55 yen.
The company also published forecasts for the fiscal year ending March 2027. It expects operating profit of 230.00 billion yen, pretax profit of 220.50 billion yen and net profit of 212.50 billion yen. The figures are based on IFRS accounting standards.
why it matters
The report shows profit growing faster than revenue, and the full-year guidance points to the strength continuing. For investors, it is a useful signal on Japan's pharmaceutical sector, although the filing does not break down the sources of income.
market impact
Shionogi shares: strong results and guidance support interest in the company's stock
- Shionogi shares pressure up — faster profit growth and higher revenue support the company's valuation
tags
instruments
sources
- Shionogi & Co 1H Net Y119.55B Vs Net Y83.00B — Dow Jones Newswires, 29 October 2026 at 04:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗